Skip to main content

Table 12 Late aortic valve complications in Inspiris Resilia versus other bioprosthesis in comparative studies (n = 5)

From: Early and late clinical outcomes and cost-effectiveness of aortic valve replacement using the Inspiris Resilia bioprosthesis

 

N

Severe PPM

Reoperation

Endocarditis

Explant

Thrombosis

SVD

NSVD

PVL

Bartus 2023 [31]

Full cohorts

Inspiris Resilia

689

NA

NA

NA

NA

NA

1.8%

NA

NA

Multiple *

936

NA

NA

NA

NA

NA

3.5%

NA

NA

Matched cohorts

Inspiris Resilia

409

NA

NA

NA

NA

NA

1.0%

NA

NA

Multiple *

380

NA

NA

NA

NA

NA

4.8%

NA

NA

Bernard 2023 [32]

Inspiris Resilia

217

15%

-

NA

NA

NA

2*

NA

NA

Magna Ease

217

16%

3

NA

NA

NA

-

NA

NA

Chiariello 2023 [35]

Inspiris Resilia

74

6

-

-

-

-

-

NA

-

Avalus

74

4

2

3

-

-

-

NA

-

Francica 2023 [40]

Inspiris Resilia

122

NA

-

NA

NA

NA

-

NA

-

Magna Ease

122

NA

4

NA

NA

NA

4

NA

-

Maeda 2023 [34]

Inspiris Resilia

64

-

NA

NA

NA

NA

-

NA

NA

Magna Ease

64

-

NA

NA

NA

NA

-

NA

NA

  1. *Carpentier–Edwards PERIMOUNT Magna Ease, Carpentier–Edwards PERIMOUNT Magna, Carpentier–Edwards PERIMOUNT, Carpentier–Edwards PERIMOUNT Theon, Other Carpentier–Edwards PERIMOUNT, Mitroflow, Trifecta/Trifecta GT, Mosaic, and other or unknown
  2. NSVD: Nonstructural Valve Deterioration, PPM: Prosthesis Patient Mismatch, PVL: Paravalvular Leak, SVD: Structural Valve Deterioration